English publications

Rose K. The Challenges of Pediatric Drug Development. Curr Ther Res Clin Exp. 2019, https://doi.org/10.1016/j.curtheres.2019.01.007

Rose K, Neubauer D, Grant-Kels JM. Questionable Industry-Sponsored Studies in children and adolescents in Slovenia. Curr Ther Res Clin Exp. 2019, https://doi.org/10.1016/j.curtheres.2019.01.002  

Rose K, Walson PD. Are Regulatory Age Limits in Pediatric Melanoma Justified? Curr Ther Res Clin Exp. 2019, https://doi.org/10.1016/j.curtheres.2019.01.003

Rose K, Grant-Kels JM. Pediatric Melanoma – The Whole (Conflicts Of Interest) Story. Int J Womens Dermatol 2018, https://doi.org/10.1016/j.ijwd.2018.10.020 

Rose K, Grant-Kels JM. FDA/EMA-triggered paediatric studies: Do they really advance child health? Regulatory Rapporteur (TOPRA) Vol 15, No 9, September 2018 – PDF available on request

Rose K, Grant-Kels JM. The Meanings of „Pediatric Drug Development“. A Review. Therapeutic Innovation and Regulatory Science 2018, https://journals.sagepub.com/doi/pdf/10.1177/2168479018812060  

Rose K, Grant-Kels JM. Questionable International Pediatric Studies in the United States and Russia Triggered by Regulatory Authorities. Asian Journal of Research in Medical and Pharmaceutical Sciences 2018,3(3). http://www.sciencedomain.org/issue/3607

Rose K, Grant-Kels JM. Pediatric Melanoma and Drug Development. Children (Basel). 2018 Mar 20;5(3). http://www.mdpi.com/2227-9067/5/3/43

Rose K, Grant-Kels JM. Questionable International Pediatric Studies With Swiss Participation. Swiss Med Wkly 2018, https://smw.ch/en/op-eds/post/questionable-pediatric-studies-with-swiss-participation/

Rose K, Grant-Kels JM. Most adolescents’ melanomas are conventional malignant adult-type melanomas. European Journal of Cancer (2018), https://doi.org/10.1016/j.ejca.2018.01.080

Rose K, Benisheva-Dimitrova T. EU paediatric investigation plans (PIPs) might harm children. Acta Med Bulg 2018, 45(1): 5-10. https://www.degruyter.com/downloadpdf/j/amb.2018.45.issue-1/amb-2018-0001/amb-2018-0001.pdf

Rose K, Walson PD: Do Pediatric Investigation Plans (PIPs) Advance Pediatric Healthcare? Pediatr Drugs 2017, 19(6), 515-522 https://www.ncbi.nlm.nih.gov/pubmed/28889403

Rose K, Walson PD: Do the European Medicines Agency (EMA) Decisions Hurt Pediatric Melanoma Patients? Clinical Therapeutics 2017, 39(2), 253-265 https://www.clinicaltherapeutics.com/article/S0149-2918(17)30047-4/pdf

Rose & Mueller 2016 Children with MS
> Download pdf

Rose K: New Drugs For Rare Diseases in Children.  Clinical Therapeutics 2017, 39(2), 246-252 https://www.clinicaltherapeutics.com/article/S0149-2918(17)30050-4/pdf

Rose & Walson 2015 – EMA Contribution to Fight Against Childhood Leukemia
> Download pdf

Rose & Kummer 2015
> Download pdf

Rose & Bar-Shalom 2014 – Pediatric Formulations Intro
> Download pdf